9
Participants
Start Date
October 31, 2013
Primary Completion Date
August 31, 2014
Study Completion Date
October 31, 2014
Dovitinib
"All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years.~If 500 mg is intolerable, 400 mg will be dosed. If 400 mg is intolerable, 300 mg will be dosed"
Georgetown University- Lombardi Cancer Center, Washington D.C.
Collaborators (1)
Novartis
INDUSTRY
Georgetown University
OTHER